Introduction
Water and mainly sodium intake is under strong control of inhibitory mechanisms from the lateral parabrachial nucleus (LPBN), a pontine structure located dorsolaterally to the superior Abbreviations: ANG II, angiotensin II; CAP, captopril; CCK, cholecystokinin; CRF, corticotrophin release factor; DOCA, deoxycorticosterone acetate; FURO, furosemide; i.c.v., intracerebroventricular; LPBN, lateral parabrachial nucleus; LV, lateral ventricle; NTS, nucleus of the solitary tract; OVLT, organum vasculosum of the lamina terminalis; s.c., subcutaneous; SFO, subfornical organ.
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E-mail address: menani@foar.unesp.br (J.V. Menani). cerebellar peduncle [6, 7, 10, 14, 26, 28, 29] . Electrolytic or neurotoxic lesions of the LPBN increase water intake induced by angiotensin II (ANG II) [15, 27, 28] . Bilateral injections of the serotonergic receptor antagonist methysergide into the LPBN increase water and/or 0.3 M NaCl intake induced by ANG II injected intracerebroventricularly (i.c.v.) or into the subfornical organ (SFO), i.c.v. injection of the cholinergic agonist carbachol, subcutaneous (s.c.) injection of deoxycorticosterone (DOCA), 24 h of sodium depletion or by the treatment with the diuretic furosemide (FURO) combined with a low dose of the angiotensin converting enzyme inhibitor captopril (CAP) [7, 8, 12, 22, 23, 25, 26] . The activation of ␣ 2 -adrenoceptors or the blockade of cholecystokinin (CCK), corticotrophin release factor (CRF) or glutamate receptors in the LPBN also increases 0.3 M NaCl intake induced by FURO + CAP, suggesting that different neurotransmitters in the LPBN modulate important inhibitory mechanisms for the control of sodium and water intake that acts by reducing or limiting the ingestion induced by different facilitatory stimuli and, therefore, contributing to satiety [3, [9] [10] [11] 18, 24] . The importance of the LPBN inhibitory mechanisms for sodium satiety is also suggested by studies that have tested the effects of GABAergic activation in the LPBN in fluid-replete rats [6, 30] . In this condition, bilateral injections of the GABA A receptor agonist muscimol into the LPBN induce a robust and rapid (within 1-4 h) ingestion of 0.3 M NaCl and water in a two-bottle test, without increasing renal sodium excretion [6, 30] . Therefore, it seems that only the deactivation of the inhibitory mechanisms with the injections of muscimol into the LPBN, without the additional activation of facilitatory mechanisms is enough to disrupt satiety and drive fluid-replete rats to ingest hypertonic NaCl [6] . However, to confirm or to refute this hypothesis it is important to investigate the involvement of facilitatory mechanisms on LPBN muscimolinduced sodium and water intake. In part, this was already tested in a previous study that showed that the ingestion of 0.3 M NaCl and water induced by muscimol injected into the LPBN was partially reduced by the i.c.v. injections of the AT 1 receptor antagonist losartan, suggesting that in this case sodium appetite depends on the blockade of the LPBN inhibitory mechanisms together with simultaneous activation of facilitatory mechanisms [30] .
Even a high dose of losartan injected i.c.v. only partially reduced LPBN muscimol induced hypertonic NaCl and water intake, suggesting that ANG II is not the only facilitatory mechanism involved on LPBN muscimol-induced sodium and water intake in fluidreplete rats. Therefore, with the purpose to find another possible facilitatory mechanism involved on LPBN muscimol-induced water and sodium intake, in the present study, we investigated the effects of the blockade of central muscarinic cholinergic receptors with i.c.v. injection of atropine on 0.3 M NaCl and water intake induced by the injections of muscimol into the LPBN in fluid-replete rats. Although central cholinergic stimulation produces no sodium intake in fluid-replete rats, the combination of central cholinergic activation with the blockade of LPBN serotonergic inhibitory mechanisms induces hypertonic NaCl intake in fluid-replete rats [22] . To show that the effects of i.c.v. atropine on water and 0.3 M NaCl intake were not due to non specific inhibition of ingestive behaviors, we tested also the effects of i.c.v. atropine on water and 0.3 M NaCl intake produced by moxonidine injected into the LPBN in rats treated with FURO + CAP s.c.
Experimental procedures

Animals
Male Holtzman rats weighing 280-320 g were used. Animals were housed in individual stainless steel cages with free access to normal sodium diet (Guabi Rat Chow, Paulínia, SP, Brazil), water and 0.3 M NaCl solution. Rats were maintained in a room with temperature at 23 ± 2 • C, humidity 55 ± 10% and a 12:12 light-dark cycle with light onset at 7:00 AM. All the experimental procedures were approved by Ethical Committee for Animal Experimentation (CEEA) from School of Dentistry of Araraquara -UNESP (CEEA 07/2008 and CEEA 31/2010). The experimental protocols followed the U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH publication no. 80-23, 1996).
Brain surgery
Rats were anesthetized with ketamine (80 mg/kg of body weight, Cristália, Itapira, Brazil) combined with xylazine (7 mg/kg of body weight, Agener União, Embu-Guaç u, Brazil) intraperitoneally, placed in a stereotaxic instrument (Kopf 900, Tujunga, CA, USA) and had the skull leveled between bregma and lambda. Stainless steel 23-gauge guide cannulas were implanted bilaterally into the LPBN (coordinates: 9.4 mm caudal to bregma, 2.1 mm lateral to midline and 4.0 mm below dura mater) and a third cannula was implanted in direction to the left lateral ventricle (LV; coordinates: 0.3 mm caudal to bregma, 1.6 mm lateral to midline and 3.6 mm below the skull). The tips of the guide cannulas were positioned at a point 2 mm above the LPBN and 1 mm above the LV. The guide cannulas were fixed to the cranium using dental acrylic resin and jeweler screws. A 30-gauge metal obturator filled the guide cannulas between tests. At the end of the surgery, the animals received an intramuscular injection of antibiotic (benzylpenicillin -80,000 IUs plus streptomycin -33 mg; Pentabiótico Veterinário -Pequeno Porte, Fort Dodge Saude Animal, Campinas, Brazil) and a s.c. injection of the analgesic/anti-inflammatory 1% ketoprofen (0.03 mL/rat; Ketoflex, Mundo Animal, São Paulo, Brazil).
After the surgery, rats were allowed to recover for 5 days before starting water and 0.3 M NaCl intake tests.
Drugs
Muscimol HBr (GABA A receptor agonist, 0.5 nmol/0.2 L) from Research Biochemicals Internationals, Natick, MA, USA and moxonidine hydrochloride (␣ 2 -adrenoceptor/imidazoline agonist, 0.5 nmol/0.2 L) a donation from Solvay Pharma, Hannover, Germany, were administered into the LPBN. Atropine methyl bromide (muscarinic receptor antagonist, 20 nmol/1 L) from Sigma Chemical Co., Saint Louis, MO, USA was administered into the LV. Atropine and muscimol were dissolved in saline (0.9% NaCl) and moxonidine was dissolved in a mix of propylene glycol and water 2:1 (vehicle).
Furosemide (natriuretic/diuretic, 10 mg/kg of body weight s.c.) from Sigma Chem., St Louis, MO, USA was dissolved in alkaline saline (pH adjusted to 9.0 with NaOH). Captopril (angiotensin converting enzyme inhibitor, 5 mg/kg of body weight s.c.) from Sigma Chem., St. Louis, MO, USA was dissolved in saline.
Central injections
Injections into the LPBN and LV were made using 5 L Hamilton syringes (Hamilton, Reno, NV, USA) connected by polyethylene tubing (PE-10) to 30-gauge injection cannula (2 mm longer than the guide cannula). The injection volumes into the LPBN and LV were 0.2 L and 1.0 L, respectively.
Water and 0.3 M NaCl intake tests 2.5.1. Tests in fluid-replete rats
Rats were tested in their home cages with no access to food during the test. Water and 0.3 M NaCl were provided from burettes with 0.1 mL divisions that were fitted with metal drinking spouts. Cumulative water and 0.3 M NaCl intake was recorded at every 30 min for 4 h starting immediately after bilateral injections of muscimol (0.5 nmol/0.2 L) or saline into the LPBN. Immediately before the LPBN injections, the rats also received injections of atropine (20 nmol/1 L) or saline into the LV. The rats were submitted to 3 tests and received the following combinations of treatments: (1) saline into the LV + saline into the LPBN; (2) saline into the LV + muscimol into the LPBN; (3) atropine into the LV + muscimol into the LPBN. In each test, the group of rats was divided in two and half of the group received one of the combination of treatments cited above and the remaining animals received another combination of treatments. The sequence of the treatments in each rat in the different tests was randomized and at the end of 3 tests each rat received all the 3 treatments.
A recovery period of at least 2 days was allowed between the tests.
Tests in FURO + CAP-treated rats
Water and 0.3 M NaCl intake was induced by s.c. injections of FURO (10 mg/kg of body weight) + CAP (5 mg/kg of body weight). Immediately after the treatment with FURO + CAP, the rats were maintained without water or 0.3 M NaCl for 1 h. After this period, water and 0.3 M NaCl were offered to the animals and the cumulative intake was recorded at every 30 min for 2 h.
Vehicle or moxonidine (0.5 nmol/0.2 L) was injected into the LPBN 15 min before the access to water and 0.3 M NaCl. Atropine (20 nmol/1 L) or saline was injected into the LV 15 min before the injections into the LPBN.
A recovery period of at least 2 days was allowed between the tests. During the tests rats had no access to food.
Histology
At the end of the last test, the rats received injections of 2% Evans Blue solution (0.2 L). They were then deeply anesthetized with sodium thiopental (Cristália, Brazil, 80 mg/kg of body weight) and perfused transcardially with saline followed by 10% formalin. Brains were removed, fixed in 10% formalin, frozen, cut in 50 m sections, stained with Giemsa stain, and analyzed by light microscopy to confirm the injection sites into the LPBN and LV.
Statistical analysis
Results are reported as means ± SEM. Two way analysis of variance (ANOVA) using treatments and times as factors followed by Newman-Keuls tests were used for comparisons. Differences were considered significant at p < 0.05. (Fig. 1) . The injections of atropine (20 nmol/1 L) i.c.v. reduced the effects of LPBN muscimol injections on 0.3 M NaCl (13.5 ± 5.0 mL/4 h) and water intake (2.9 ± 1.6 mL/4 h) (Fig. 1). 
Results
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Water and 0.3 M NaCl intake induced by FURO + CAP in rats treated with moxonidine into the LPBN combined with i.c.v. injection of atropine
In rats pre-treated with saline i.c.v., bilateral injections of moxonidine (0.5 nmol/0.2 L) into the LPBN increased FURO + CAPinduced 0.3 M NaCl intake (36.5 ± 9.8 mL/2 h, vs. vehicle into LPBN: 5.6 ± 2.0 mL/2 h) [F(2,12) = 5.97; p < 0.05] (Fig. 2) . The pre-treatment with atropine (20 nmol/1 L) injected i.c.v. did not change 0.3 M NaCl intake produced by combining FURO + CAP s.c. with moxonidine injected into the LPBN (26.8 ± 6.2 mL/2 h) ( (Fig. 2) .
Discussion
The present results show that water and 0.3 M NaCl intake induced by bilateral injections of muscimol into the LPBN in fluid-replete rats was reduced by i.c.v. injection of the muscarinic cholinergic antagonist atropine, suggesting that central cholinergic mechanisms probably from the forebrain facilitate 0.3 M NaCl and water intake when the inhibitory mechanisms are deactivated with bilateral injections of muscimol into the LPBN. The i.c.v. injection of atropine did not affect water and 0.3 M NaCl intake in rats treated with FURO + CAP combined with injections of moxonidine into the LPBN, confirming that the reduction of LPBN muscimol-induced water and sodium intake is not due to non specific inhibition of ingestive behaviors by the i.c.v. injection of atropine. At the dose tested (20 nmol/1 L), atropine injected into the LV almost abolished water intake induced by the cholinergic agonist carbachol (4 nmol/1 L) also injected into the LV (1.9 ± 1.0 mL/2 h, vs. saline + carbachol into the LV: 8.6 ± 1.5 mL/2 h; n = 5), demonstrating that this dose of atropine is effective in blocking central muscarinic receptors. Muscimol injected into the LPBN in fluid-replete rats induces only a small ingestion of water when only water is available [6] , suggesting that the strong ingestion of water by fluid-replete rats treated with muscimol into the LPBN when both water and 0.3 M NaCl are simultaneously available is likely a consequence of the increased osmolarity of body fluids due to the excessive ingestion of hypertonic NaCl. Therefore, the main reason for the reduced ingestion of water caused by the i.c.v. injection of atropine in rats treated with muscimol into the LPBN is probably the reduced ingestion of hypertonic NaCl. However, considering the importance of the central cholinergic mechanisms for water deprivation-or hyperosmolarity-induced water intake [5, 21] , it is not possible to completely exclude a direct effect of central muscarinic blockade reducing water intake.
Similar to the increase in plasma osmolarity, central cholinergic activation induces water intake and was suggested to inhibit sodium intake [16, 17] . In spite of this classical concept, the i.c.v. injection of the cholinergic agonist carbachol stimulates hypertonic NaCl intake in fluid-replete rats treated with bilateral injections of the serotonergic antagonist methysergide into the LPBN, suggesting that, besides water intake, central cholinergic mechanisms also facilitate sodium intake when LPBN inhibitory mechanisms are deactivated [22] . To explain the paradoxical facilitation of hypertonic NaCl intake by a mechanism recognized as inhibitory for sodium intake like increased plasma osmolarity, De Luca Jr et al. [13] proposed that plasma hyperosmolarity simultaneously activates two parallel central circuitries: one that facilitates thirst and sodium appetite and another dependent on the LPBN that inhibits sodium intake. The activity of the inhibitory mechanism completely opposes to the action of the facilitatory mechanism and the result is no sodium intake by hyperosmotic rats. However, the activation of facilitatory mechanisms by the hyperosmolarity drives rats to ingest hypertonic NaCl besides water if the LPBN inhibitory mechanisms were deactivated [4, 13] . Mechanisms similar to those proposed to explain the effects of increased osmolarity on sodium intake might also explain the suggested opposite effects of the central cholinergic mechanisms on sodium intake.
In the present study, rats were fluid-replete and, therefore, probably satiated. In this condition it was expected that the facilitatory mechanisms were deactivated and the action of the inhibitory mechanisms, if they were activated, not so important to maintain satiety in the absence of the activity of facilitatory mechanisms. However, the strong ingestion of 0.3 M NaCl by rats treated with muscimol injected into the LPBN suggests exactly the opposite, i.e. that sodium appetite in a condition of satiety is under strong control of the inhibitory mechanisms. The present and the previous studies [30] suggest that LPBN inhibitory mechanisms are essential to maintain sodium satiety and that central angiotensinergic and cholinergic mechanisms may stimulate sodium intake if the LPBN inhibitory mechanisms were deactivated in fluid-replete rats. Even considering that the cholinergic mechanisms may also inhibit sodium intake, as commented above, the blockade of LPBN mechanisms might abolish the inhibitory effect and, then, the result of the central cholinergic activation in rats treated with muscimol into the LPBN is also the facilitation of hypertonic NaCl ingestion.
Although i.c.v. atropine reduced LPBN muscimol-induced water and sodium intake, the same i.c.v. treatment produced no change of water and 0.3 M NaCl intake induced by FURO + CAP in rats treated with moxonidine into the LPBN, suggesting that central cholinergic mechanisms are not involved in the ingestion of sodium or water in this condition and, therefore, that the effects of i.c.v. atropine are not due to non-specific inhibition of ingestive behaviors. Moxonidine acting on ␣ 2 adrenoceptors in the LPBN increases water and sodium intake induced by FURO + CAP, i.e. increases an ingestion caused by ANG II acting on central AT 1 receptors in fluid depleted rats, however, moxonidine injected into the LPBN produces no change of water or sodium intake in fluid-replete rats [3] . Therefore, moxonidine injected into the LPBN only affects NaCl and water intake if a facilitatory mechanism like ANG II is simultaneously activated [3] . The difference in the condition for muscimol and moxonidine injected into the LPBN to produce effects on sodium and water intake is likely related to which inhibitory signals are affected by each treatment. Moxonidine injected into the LPBN increases hedonic and reduces aversive responses to an intra-oral infusion of 0.3 M NaCl, suggesting that moxonidine acting in the LPBN reduces the influence of inhibitory taste signals activated by the ingestion of hypertonic NaCl, increasing the palatability of NaCl and consequently the ingestion of hypertonic NaCl [2] . Besides taste signals, other inhibitory signals like those from peripheral baroreceptors and cardiopulmonary receptors also reach the LPBN. It seems that, muscimol acting in the LPBN removes all the inhibitory signals involved in the control of sodium intake and, therefore, in this condition any baseline angiotensinergic or cholinergic facilitatory signal still present in fluid-replete rats is enough to disrupt satiety and to drive satiated rats to ingest NaCl [6, 30] the present results]. Probably baseline levels of ANG II and acetylcholine activate the respective receptors in the SFO and the organum vasculosum of the lamina terminalis (OVLT). The SFO sends projections to the central nucleus of the amygdala (CeA), which also receives projections from the LPBN [19, 20] . Sodium intake produced by blockade of LPBN neurons with muscimol depends on the integrity of the CeA [1] . Therefore, it seems that signals from the SFO and OVLT reach CeA and in this area they are modulated by the inhibitory signals from the LPBN. However, with the information available it is not possible to exclude that a different area, still unknown, integrates the facilitatory signals from the CeA and the inhibitory signals from the LPBN.
In conclusion, the present results show that central cholinergic mechanisms stimulate 0.3 M NaCl and water intake if the inhibitory mechanisms were deactivated by muscimol injected into the LPBN in fluid-replete rats. This suggests that the action of LPBN mechanisms inhibits facilitatory signals produced by the activity of central cholinergic mechanisms to maintain satiety in fluid-replete rats.
